Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer Read more about Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer
Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project Read more about Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
Circulating tumor DNA analysis for patients with oncogene-addicted NSCLC with isolated central nervous system progression Read more about Circulating tumor DNA analysis for patients with oncogene-addicted NSCLC with isolated central nervous system progression
Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non–Small-Cell Lung Cancer Read more about Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non–Small-Cell Lung Cancer
Evolution of immune escape mechanisms in the progression from preinvasive to invasive human lung adenocarcinoma Read more about Evolution of immune escape mechanisms in the progression from preinvasive to invasive human lung adenocarcinoma
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial Read more about BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay Read more about Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay
Outcomes in oncogenic-addicted advanced NSClC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay Read more about Outcomes in oncogenic-addicted advanced NSClC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay
Atlas of Transcription Factor Binding Sites from ENCODE DNase Hypersensitivity Data across 27 Tissue Types Read more about Atlas of Transcription Factor Binding Sites from ENCODE DNase Hypersensitivity Data across 27 Tissue Types
Successful treatment with enasidenib, bortezomib, and dexamethasone for the synchronous occurrence of IDH2-positive acute myeloid leukemia and multiple myeloma Read more about Successful treatment with enasidenib, bortezomib, and dexamethasone for the synchronous occurrence of IDH2-positive acute myeloid leukemia and multiple myeloma